"A Study to Investigate the Transition of Children From 'Artisanal Cannabidiol (CBD) to Epidiolex"

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 2, 2026

Primary Completion Date

February 2, 2028

Study Completion Date

December 31, 2028

Conditions
Dravet Syndrome (DS)Lennox-Gastaut Syndrome (LGS)
Interventions
DRUG

Epidiolex 100 mg/mL Oral Solution

The participant's 'artisanal' CBD and Epidiolex dose should be taken consistently with food or consistently without food throughout the entire study. The participant's dosing with or without food should be consistent with their method of dosing of 'artisanal' CBD prior to screening. Oral administration is recommended. When necessary, Epidiolex can be enterally administered via silicone feeding tubes, such as nasogastric or gastrostomy tubes.

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

Alberta Children's Hospital

OTHER

collaborator

BC Children's Hospital Research Institute

OTHER

lead

Elizabeth Donner

OTHER